Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMCWSJP)

• Drug Name: SCH51866 Drug Info
• Synonyms: SCH 51866; SCH-51866

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

• Cross-matching ID:
  PubChem CID: 5311355
  CAS Number: CAS 167298-74-0
  TTD Drug ID: DMCWSJP

Molecule-Related Drug Atlas

Drug(s) Targeting Phosphodiesterase 5A (PDE5A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tadalafil	DMJZHT1	Benign prostatic hyperplasia	GA90	Approved	[5]
Udenafil	DM1IQRP	Erectile dysfunction	HA01.1	Approved	[6]
Vardenafil	DMTBGW8	Cystic fibrosis	CA25	Approved	[7]
Dipyridamole	DMXY30O	Atrial fibrillation	BC81.3	Approved	[8]
Papaverine	DMCA9QP	Brain ischaemia	8B1Z	Approved	[9]
Avanafil	DM75CXN	Erectile dysfunction	HA01.1	Approved	[10]
Rhucin	DM3ADGP	Erectile dysfunction	HA01.1	Approved	[11]
ICARIIN	DMOJQGT	N. A.	N. A.	Phase 3	[12]
EXISULIND	DMBY56U	Colorectal cancer	2B91.Z	Phase 3	[13]
PF-489791	DM3C8GQ	Chronic obstructive pulmonary disease	CA22	Phase 2	[14]

Drug(s) Targeting Phosphodiesterase 9 (PDE9)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
PF-4447943	DM81D4I	Alzheimer disease	8A20	Phase 2	[15]
ASP-4901	DMZUAH2	Genitourinary disease	GA0Z-GC8Z	Phase 2	[16]
E2027	DMK8SY6	Lewy body dementia	6D82	Phase 2	[17]
BI-409306	DMJFDS0	Alzheimer disease	8A20	Phase 2	[18]
IMR-687	DM15MRZ	Sickle-cell disorder	3A51	Phase 2	[19]
CRD-740	DMRTX0K	Heart failure	BD10-BD13	Phase 2	[20]
TT-00920	DMP6G0P	Heart failure	BD10-BD13	Phase 1	[21]
PF-4181366	DMC8G4S	Cognitive impairment	6D71	Investigative	[22]

Drug(s) Targeting Phosphodiesterase 7B (PDE7B)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
PF-3557156	DMITYCN	Pain	MG30-MG3Z	Discontinued in Phase 1	[23]
BRL50481	DMV2XUM	Discovery agent	N.A.	Investigative	[24]

Drug(s) Targeting Phosphodiesterase 1B (PDE1B)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
US10034861, Example 165	DMD8FS5	N. A.	N. A.	Patented	[25]
US10092575, Example 101	DMU8CAD	N. A.	N. A.	Patented	[26]
US10034861, Example 164	DM27SFD	N. A.	N. A.	Patented	[25]
AC1MOZOL	DM6293C	N. A.	N. A.	Patented	[27]
US9073936, 1	DMZD1L5	N. A.	N. A.	Patented	[28]
US9073936, 2	DMZH3MX	N. A.	N. A.	Patented	[28]
US10092575, Example 158	DM7MNE2	N. A.	N. A.	Patented	[26]
AC1LDDOQ	DMKTMCH	N. A.	N. A.	Patented	[26]
US10034861, Example 1	DMLJV01	N. A.	N. A.	Patented	[25]
US10092575, Example 141	DMT47DF	N. A.	N. A.	Patented	[29]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Phosphodiesterase 1A (PDE1A)	TT73TEJ	PDE1A_HUMAN	Inhibitor	[2]
Phosphodiesterase 1B (PDE1B)	TT3ZS42	PDE1B_HUMAN	Inhibitor	[2]
Phosphodiesterase 1C (PDE1C)	TTW2HRK	PDE1C_HUMAN	Inhibitor	[2]
Phosphodiesterase 5A (PDE5A)	TTJ0IQB	PDE5A_HUMAN	Inhibitor	[2]
Phosphodiesterase 7B (PDE7B)	TTWIEY9	PDE7B_HUMAN	Inhibitor	[3]
Phosphodiesterase 9 (PDE9)	TTZOEBC	PDE9A_HUMAN	Inhibitor	[4]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5270).
• [2] Antiplatelet and antiproliferative effects of SCH 51866, a novel type 1 and type 5 phosphodiesterase inhibitor. J Cardiovasc Pharmacol. 1996 Dec;28(6):862-9.
• [3] Identification of human PDE7B, a cAMP-specific phosphodiesterase. Biochem Biophys Res Commun. 2000 May 19;271(3):575-83.
• [4] Isolation and characterization of PDE9A, a novel human cGMP-specific phosphodiesterase. J Biol Chem. 1998 Jun 19;273(25):15559-64.
• [5] Pulmonary arterial hypertension: the most devastating vascular complication of systemic sclerosis. Rheumatology (Oxford). 2009 Jun;48 Suppl 3:iii25-31.
• [6] Increased expression of the nitric oxide synthase gene and protein in corpus cavernosum by repeated dosing of udenafil in a rat model of chemical d... Asian J Androl. 2009 Jul;11(4):435-42.
• [7] The effect of vardenafil, a potent and highly selective phosphodiesterase-5 inhibitor for the treatment of erectile dysfunction, on the cardiovascular response to exercise in patients with coronary artery disease. J Am Coll Cardiol. 2002 Dec 4;40(11):2006-12.
• [8] Anti-platelet therapy: phosphodiesterase inhibitors.Br J Clin Pharmacol.2011 Oct;72(4):634-46.
• [9] Effects of icariin on cGMP-specific PDE5 and cAMP-specific PDE4 activities. Asian J Androl. 2003 Mar;5(1):15-8.
• [10] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [11] cGMP-hydrolytic activity and its inhibition by sildenafil in normal and failing human and mouse myocardium. J Pharmacol Exp Ther. 2009 Sep;330(3):884-91.
• [12] Potent inhibition of human phosphodiesterase-5 by icariin derivatives. J Nat Prod. 2008 Sep;71(9):1513-7.
• [13] Exisulind induction of apoptosis involves guanosine 3',5'-cyclic monophosphate phosphodiesterase inhibition, protein kinase G activation, and attenuated beta-catenin. Cancer Res. 2000 Jul 1;60(13):3338-42.
• [14] Highlights of the society for medicinesresearch symposium held december 10th 2009 at the national heart and lung institute, London, UK. Drugs of the Future 2010, 35(4): 349-358.
• [15] A multicenter, double-blind, placebo-controlled trial of the PDE9A inhibitor, PF-04447943, in Alzheimer's disease. Curr Alzheimer Res. 2014;11(5):413-21.
• [16] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800033070)
• [17] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [18] Clinical pipeline report, company report or official report of Boehringer Ingelheim pipeline.
• [19] Clinical pipeline report, company report or official report of Imara.
• [20] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2023. Adis Insight
• [21] Clinical pipeline report, company report or official report of TransThera Biosciences
• [22] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1309).
• [23] Company report (Pfizer pipeline: October 28, 2008)
• [24] New classes of PDE7 inhibitors identified by a fission yeast-based HTS. J Biomol Screen. 2010 Apr;15(4):359-67.
• [25] 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors. US10034861.
• [26] Substituted thiophene- and furan-fused azolopyrimidine-5-(6H)-one compounds. US10092575.
• [27] Inhibitors of phosphodiesterase 11 (PDE11). US9173884.
• [28] Organic compounds. US9598426.
• [29] Therapeutic thiophene-, furan-, and pyridine-fused azolopyrimidin-5-(6h)-ones. US10105367.